159 related articles for article (PubMed ID: 15188223)
1. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
Arch Pharm (Weinheim); 2004 Jun; 337(6):335-48. PubMed ID: 15188223
[TBL] [Abstract][Full Text] [Related]
2. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action II: contribution of drug inactivation, cellular drug uptake and sterical factors in the drug-target interaction to the antitumor activity.
Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
Arch Pharm (Weinheim); 2004 Jun; 337(6):349-59. PubMed ID: 15188224
[TBL] [Abstract][Full Text] [Related]
3. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
[TBL] [Abstract][Full Text] [Related]
4. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
von Angerer E; Birnböck H; Knebel N
Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
[TBL] [Abstract][Full Text] [Related]
5. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
Gust R; Niebler K; Schönenberger H
J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
[TBL] [Abstract][Full Text] [Related]
6. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
Gust R; Faderl M; Schönenberger H
J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
[TBL] [Abstract][Full Text] [Related]
7. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
8. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
[TBL] [Abstract][Full Text] [Related]
9. Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.
Schertl S; Hartmann RW; Batzl-Hartmann C; Spruss T; Maucher A; von Angerer E; Schiller CD; Schneider MR; Gust R; Schönenberger H
J Cancer Res Clin Oncol; 2007 Mar; 133(3):153-67. PubMed ID: 17024493
[TBL] [Abstract][Full Text] [Related]
10. Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2- phenylethylenediamine]sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring, II: Correlation of molecular structure and estrogenic activity of breast and prostate cancer inhibiting. [erythro-1-(2,6-dichloro-4-hydroxyphenyl)-2-(2-halo-4- hydroxyphenyl)ethylenediamine]platinum(II) complexes.
Gust R; Schönenberger H; Klement U; Range KJ
Arch Pharm (Weinheim); 1993 Dec; 326(12):967-76. PubMed ID: 8122966
[TBL] [Abstract][Full Text] [Related]
11. Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes.
Gust R; Schönenberger H
Arch Pharm (Weinheim); 1993 Jul; 326(7):405-13. PubMed ID: 8357303
[TBL] [Abstract][Full Text] [Related]
12. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
[TBL] [Abstract][Full Text] [Related]
13. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
[TBL] [Abstract][Full Text] [Related]
14. A-ring substituted estrogens as inhibitors of the MXT transplantable mammary ductal carcinoma.
Brooks SC; Horwitz JP; Odden D; Corbett T
Cancer Res; 1987 Sep; 47(17):4623-9. PubMed ID: 3040228
[TBL] [Abstract][Full Text] [Related]
15. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
Spruss T; Schertl S; Schneider MR; Gust R; Bauer K; Schönenberger H
J Cancer Res Clin Oncol; 1993; 119(12):707-16. PubMed ID: 8408183
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterisation of estrogenic carriers for cytotoxic Pt(II) fragments: biological activity of the resulting complexes.
Gabano E; Cassino C; Bonetti S; Prandi C; Colangelo D; Ghiglia A; Osella D
Org Biomol Chem; 2005 Oct; 3(19):3531-9. PubMed ID: 16172691
[TBL] [Abstract][Full Text] [Related]
17. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
[TBL] [Abstract][Full Text] [Related]
18. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
19. Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action.
Park H; Aiyar SE; Fan P; Wang J; Yue W; Okouneva T; Cox C; Jordan MA; Demers L; Cho H; Kim S; Song RX; Santen RJ
Cancer Res; 2007 Jun; 67(12):5717-26. PubMed ID: 17575138
[TBL] [Abstract][Full Text] [Related]
20. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice.
Chen J; Hui E; Ip T; Thompson LU
Clin Cancer Res; 2004 Nov; 10(22):7703-11. PubMed ID: 15570004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
